Natera

Director, Business Development

United States

Natera Logo
Not SpecifiedCompensation
Mid-level (3 to 4 years), Senior (5 to 8 years)Experience Level
Full TimeJob Type
UnknownVisa
Life Sciences, Diagnostics, HealthcareIndustries

Requirements

Candidates should possess a Bachelor’s degree in healthcare, life sciences, pharmacy, or a related field, with an MBA or Ph.D. being preferred. They must have at least 3+ years of experience in business development, sales, investment banking, or management consulting, and a track record of leading and closing strategic collaboration and licensing agreements. Industry background in diagnostics, software, life sciences, or private equity/venture capital is required.

Responsibilities

The Director of Business Development will evaluate external growth opportunities, represent Natera in negotiations with partners, customers, and suppliers, develop a comprehensive BD strategy to achieve company growth objectives, work with the Business Development team on cross-selling opportunities, penetrate targeted accounts, identify opportunities, manage the selling process, assess growth opportunities, lead cross-functional diligence teams, and negotiate transactions.

Skills

Business Development
Negotiation
Strategic Planning
Financial Modeling
Leadership
Communication
Diagnostics
Life Sciences
Investment Banking
Management Consulting

Natera

Genetic testing and diagnostics solutions provider

About Natera

Natera focuses on genetic testing and diagnostics, providing advanced solutions for cancer patients, transplant patients, and individuals assessing hereditary health risks. Their main technology is cell-free DNA (cfDNA) testing, which analyzes DNA fragments in the blood to detect minimal traces of cancer and assess organ health. Natera stands out by offering specialized tests like the Signatera ctDNA test and Panorama NIPT, along with genetic counseling services. The company's goal is to improve patient care and health outcomes through accurate genetic testing.

Key Metrics

Austin, TexasHeadquarters
2004Year Founded
$149.9MTotal Funding
IPOCompany Stage
Biotechnology, HealthcareIndustries
1,001-5,000Employees

Benefits

Flexible medical plans
Investment options
Time off
Workplace perks

Risks

Hindenburg report accuses Natera of deceptive sales practices, risking legal challenges.
New Prospera Heart features may face slow adoption by healthcare providers.
Fetal RhD NIPT demand may drop post-RhIg shortage, affecting future sales.

Differentiation

Natera's Signatera test offers personalized ctDNA analysis for cancer patients.
Prospera Heart test uses unique Donor Quantity Score for transplant rejection detection.
Panorama NIPT test is a leader in non-invasive prenatal testing with 2 million tests.

Upsides

Increased adoption of liquid biopsy techniques boosts demand for Natera's cfDNA tests.
AI integration enhances accuracy and speed of Natera's cfDNA analysis.
Growing personalized medicine trend aligns with Natera's customized genetic tests.

Land your dream remote job 3x faster with AI